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Hepatocyte paraffin I is a monoclonal antibody
that has been developed speciflcaly to react
with hepatocytes in routine formalin-fixed and
paraffin-embedded surgicalpathology tissues. It
results in a distinct, granular cytoplasmic stain-
ing ofhepatocytes butfails to react with bile ducts
and nonparenchymal liver ceUls. The antibody
decorates a majority of hepatocelular carcino-
mas, includingfibrolamellar variants. Itfails to
react with a wide variety of other adult malig-
nancies, with the exception offocal staining in a
few gastrointestinal malignancies, including a
subpopulation of gastric carcinomas. (Am J
Pathol 1993, 143:1050-1054)
Panels of antibodies useful in evaluating primary and
secondary liver tumors include a-fetoprotein, a-1-
antitrypsin, monoclonal carcinoembryonic antigen,
polyclonal carcinoembryonic antigen cross-reactive
for biliary glycoprotein, antibodies to cytokeratins,
and neuroendocrine markers such as chromogranin.
1-3 We have developed a new monoclonal antibody,
hepatocyte paraffin 1 (Hep Par 1), that reacts with
both normal and neoplastic hepatocytes in routine
formalin-fixed, paraffin-embedded tissues. We have
evaluated this antibody in a retrospective analysis of
adult human tumors, with and without metastases,




The immunogen was obtained from a 10% neutral
buffered, formalin-fixed, failed allograft liver that
was mechanically disrupted. Six-week-old female
Balb/C mice received serial injections of the immu-
nogen. Animal use protocols had prior approval of
the Institutional Animal Care and Use Committee of
the University of Pittsburgh. Fusion was by a stan-
dard method and based on a modification of Kohler
and Milstein.4 The myeloma cells (P3X63-Ag8.653)
and fusion protocols were a generous gift from Dr.
Howard Reisner (UNC Chapel Hill, NC).5--
Screening
Positive wells were screened by evaluating staining
patterns of supernatants on microscope slides, con-
taining multiple sections of nondigested, formalin-
fixed human tissues, by immunoperoxidase using a
mouse immunoglobulin G (IgG) ABC kit (Vector
Laboratories, Burlingame, CA). One well that was
highly specific for adult and fetal liver was sub-
jected to single cell cloning and is the subject of
this report.
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Cloning, Class, and Isotyping
The antibody was classed as an IgGl K. Single cell
cloning by limiting dilution and antibody classifying
was performed by Drs. Albert DeLeo and Lina Lu of
the Hybridoma Facility of the Pittsburgh Cancer In-
stitute.
Supernatant
Clone OCH1E5.2.10 (Hep Par 1) supernatant was
collected in batch for the study described herein.
For control of nonspecific binding of IgG in tissue
sections, the supernatant from the parental my-
eloma cell line was spiked with purified mouse IgG
(Chemicon, El Segundo, CA).
Selection and Immunoperoxidase
Evaluation of Tissues
All cases were routine surgical pathology tissues that
had been fixed in 10% neutral buffered formalin and
paraffin-embedded. Metastases were those that
came at the time of the original resection or biopsy
with the exception of second-stage lymph node dis-
sections. Staining times for primary and control su-
pernatants were for 90 minutes, and staining times for
the biotinylated secondary and avidin-biotin complex
reagents were for 60 minutes each. 3-amino-9-
ethylcarbazole (AEC) (Biomeda, Foster City, CA) was
used as the chromogen for 10 minutes.
Results
In histologically normal adult human livers, Hep Par
1 detects an antigen that is localized to the hepato-
cyte cytoplasm. No staining of bile ducts or other
nonparenchymal cells is seen. The pattern is dis-
tinctly granular, occasionally ringlike, and is present
diffusely throughout the hepatocyte cytoplasm with-
out canalicular accentuation (Figure 1A). A similar
pattern was seen in a 17-week gestation human fe-
tal liver. There does not seem to be any zonal pref-
erence in normal liver; however, in the liver immedi-
ately adjacent to tumors decreased staining in
compressed hepatocytes may be seen (Figure 1B
and Figure 2D). Many of the HCCs arose in cirrhotic
Figure 1. A: Otiginial screening slide, Hep Par 1-positive hepatocytes adjacent to nonstaining netnroentdocrine tumor ( 400X). B: Moderately differ-
enitiated HCC nodule.s strongly Hep Par I-positive. Intervening liver uith comipression (IOOX). C: Cirrhotic liver with heterogenous Hep Par I posi-
tivity. Bile ducts Hep Par 1-negative (200X). D: Positive Hep Par 1 staining in HCC (200X).
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livers and often regenerative nodules showed heter-
ogeneous Hep Par 1 expression (Figure 1C). In fatty
livers, Hep Par 1 positivity was maintained in the cy-
toplasm adjacent to fat vacuoles. Other normal
adult human tissues, including skin, smooth and
skeletal muscle, mesothelium, lymph nodes, spleen,
lung, breast, esophagus, stomach, intestine, pan-
creas, biliary tract, kidney, urinary bladder, adrenal,
prostate, endometrium, and ovary, were almost all
negative for Hep Par 1 reactivity. The rare excep-
tions are noted below.
Table 1 gives the results of Hep Par 1 staining in a
variety of adult human malignancies. The majority of
HCCs were positive for Hep Par 1 expression (Figure
1, B and D). The staining pattern within individual
tumor cells maintained its granular cytoplasmic dis-
tribution; however, there could be considerable vari-
ability from one area to another, best demonstrated in
larger samples. Four HCCs had only rare positivity,
and of these, one had a negative lymph node me-
tastasis. Occasionally, accentuated staining was
seen in tumor areas adjacent to vascularized fibrous
septa and in the edges of tumor trabeculae. All five
fibrolamellar HCCs were Hep Par 1-positive. Only
one sclerosing HCC was available for inclusion in
this study, and it was entirely Hep Par 1-negative.
A large number of non-HCC tumors were se-
lected to include biliary tract and gall bladder, pan-
creas, intestinal, and neuroendocrine tumors be-
cause these tumors frequently enter into the
pathological differential diagnosis of liver cancer.
The normal biliary tract does not show immunohis-
tologically demonstrable Hep Par 1 expression.
Cholangiocarcinomas and bile duct tumors were
predominately negative (Figure 2A). Only two of 31
cholangiocarcinomas and bile duct tumors showed
any Hep Par 1 positivity; this positivity was a minor,
focal component seen in one postirradiation cholan-
giocarcinoma arising in an intrahepatic duct and in
one intraductal papillary adenocarcinoma. Focal
staining of inflammed, but nonmalignant, hilar bile
ducts was an exceptional finding in a case of chol-
angiocarcinoma arising in a patient with Caroli's dis-
ease. Three of 12 pancreatic adenocarcinomas
showed rare cells with Hep Par 1 positivity (two mu-
cinous cystadenocarcinomas and one adenocarci-
Figure 2. A: A typical cholangiocarcinoma (Hep Par 1-negative) and liver interface (200X). B: Hep Par 1 positivity seen -in villousfronds of right
colon polyp yet underlying infiltrating adenocarcinoma Hep Par 1-negative (200X). C: Hep Par 1-positive liver with negatively stained metastatic
renal cell carcinoma (iOOX). D: Wedge biopsy ofHep Par 1-positive liver with negatively stained metastatic adenocarcinoma of the colon (40x).
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Table 1. Hep Par 1 Staining
Primaries: Metastases:
HepPar+/ HepPar+/






























































Intrahepatic (24); bile duct
(7); gallbladder (4)

























*Rare (+) in 1 intrahepatic
chol. s/p radiation; *rare







*4 HCC only rare
positive cells
*Rare (+) cells in 2/2
mucinous cystadeno;
*rare (+) cell in 1






noma of the head of the pancreas). Nonpulmonary
neuroendocrine tumors were negative, including 14
specimens from liver, pancreas, and small intestine.
Gastric adenocarcinomas (all were poorly differenti-
ated, signet ring, or mixed intestinal/signet ring)
were negative, with the exception of three cases
showing focal, but strong, Hep Par 1 expression.
The residual gastric mucosa, including mucosa with
intestinal metaplasia, was Hep Par 1-negative.
Whereas all small bowel adenocarcinomas, includ-
ing those appearing to arise in villous polyps, were
Hep Par 1-negative, there does seem to be a pro-
pensity for nonmalignant small bowel mucosa to
stain focally, but often intensely, in a minority of
cases. Four of the cases in this series displayed fo-
cal Hep Par 1 expression in benign small intestinal
mucosa. The Hep Par 1-positive pattern in the small
bowel appeared as cytoplasmic granules in ab-
sorptive enterocytes of the surface and neck region.
One poorly differentiated right-sided colon adeno-
carcinoma, seeming to arise in an overlying villous
tumor, had strong Hep Par 1 expression in the over-
lying villous tumor but lacked expression in the infil-
trating tumor (Figure plate 2, B).
Other tumors included in this study were Hep Par
1-negative. Adjacent non-neoplastic tissues, when
present, were also negative. The sole exception was
the presence of Hep Par 1-positive hepatocytes ad-
jacent to secondary, metastatic tumors (Figure 2, C
and D).
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Discussion
Unlike a-feto protein, the antigen detected by Hep
Par 1 does not seem to be an oncofetal antigen as
it has been immunohistologically localized in both
fetal and adult liver. As it is present in normal hu-
man liver, it is also not a tumor-associated antigen.
Hep Par 1 does, however, seem to be conserved in
most adult HCCs, including fibrolamellar variants.
For the evaluation of primary and secondary liver
tumors, Hep Par 1 expression may be detected in a
larger proportion of HCCs than is seen with AFP.
Like AFP, it can be seen occasionally in other endo-
dermally derived tissues.8
The monoclonal antibody, Hep Par 1, is highly,
but not absolutely, specific for hepatocytes and re-
sults in a very distinct granular cytoplasmic staining
in these cells. Occasionally, within the granules, a
ringlike staining pattern is noted, suggesting that
the antigen may be localized to the membrane of a
cytoplasmic organelle. The fact that they are dif-
fusely distributed throughout the cytoplasm and do
not cluster near the canaliculus would argue
against this being an endoplasmic reticulum/
microsome-associated antigen. Their presence in
such large numbers and their size (approximately
0.5 to 2 p), would make them unlikely to be per-
oxisomes. A likely candidate would be a
mitochondrial-associated antigen, although the lack
of staining of mitochondrial-rich kidney tubules and
skeletal muscle would suggest that it is not a ubiqu-
itious mitochondrial antigen. Preliminary data (re-
sults not shown) have localized the antigen to the
mitochondrial fraction of rat liver homogenates.
The decreased Hep Par 1 expression seen as a
compression rim in the liver adjacent to some tu-
mors and the perivascular accentuation seen in
some HCCs may represent a probable effect of
blood shunting. A similar vascular shunting in cir-
rhotic livers may account for the heterogeneous ex-
pression seen in regenerative nodules. Staining with
Hep Par 1 is very crisp and does not result in back-
ground staining of serum. We have not yet at-
tempted to determine whether the Hep Par
1-detected antigen is present in human sera. Hep
Par 1 does give similar staining patterns in formalin-
fixed liver as well as in acetone-permeabilized fro-
zen cryostat sections of liver, suggesting that the
antibody can be used to detect native, nondena-
tured antigen. Work to isolate the antigen is cur-
rently underway.
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